cloning of tissue plasminogen activator cdna in nonpathogenic leishmania

نویسندگان
چکیده

introduction: at present, most recombinant proteins are produced in prokaryotes especially e coli. yeasts and cho also are used as eukaryotic hosts. leishmania tarentolae, a parasite of lizards, a member of trypanosomatidae family is one of the new systems for expression of heterologous proteins. in this system, some of the parasitic protozoa features are used in expression of mammalian proteins. material and methods: for evaluation of the protozoa for expression of human complex proteins, we cloned cdna of tpa gene containing native human signal sequence. we used vectors containing 3´ and 5´ sequences of leishmania 18s rrna for integration of the vectors in 18s rrna gene and severe transcription. results: rt-pcr test showed production of specific mrna of tpa gene in the recombinant cells. southern blot analysis confirmed the cloning of t-pa in the genome of the leishmania. conclusion: this study showed native human signal sequence mediate transport and secretion of the protein. hence, l. tarentolae is the first useful biotechnologically protozoan and tpa is the most complex protein expressed in it.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.

Full-length cDNA for plasminogen activator inhibitor (PAI-1) was isolated from a human umbilical vein endothelial cell (HUVEC) lambda gt11 cDNA library. Three overlapping clones were identified by immunologic screening of 10(6) recombinant phage using a rabbit anti-human fibrosarcoma PAI-1 antiserum. The fusion proteins encoded by these three clones also react strongly with a monoclonal mouse a...

متن کامل

The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...

متن کامل

Optimizing refolding condition for recombinant tissue plasminogen activator

Low molecular size additives such as L-arginine and the redox compounds have been used both in the culturemedium and in vitro refolding to increase recombinant proteins production. Additives increase proteinrefolding and yield of active proteins by suppressing aggregate formation or enhancing refolding process.In this work, a comparative study was performed on refolding of rec...

متن کامل

Alu DNA Polymorphism of Human Tissue Plasminogen Activator (tPA) Gene in Diabetic Jordanian Patients Patients

Background: Hypercoagulability and hypofibrinolysis are among the symptoms exhibited by diabetic patients. Our study aimed to address the polymorphic nature of Alu DNA fragment in the human tissue plasminogen activator gene within diabetes mellitus (DM) Jordanian patients. Methods: Genomic DNA was isolated from 76 DM patients and 60 non-diabetic Jordanian individuals, and the Alu fragment was a...

متن کامل

Dual frequency ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro human clot model

Introduction: Stroke causes death and disability in patients throughout the world. At present, the only FDA- approved drug for ischemic stroke is recombinant tissue plasminogen activator (rt- PA). Unfortunately, rtPA can cause intracerebral hemorrhage and must use within limited time window (within 3-4.5 hour after onset of stroke). Ultrasound with rtPA loaded liposomes (rtPA_L...

متن کامل

evaluation of prognostic values of tissue plasminogen activator and plasminogen activator inhibitor-1 in crimean-congo hemorrhagic fever patients

results a total of 46 patients participated in this study. the significant differences between recovering patients and the patients who died, regarding aspartate aminotransferase (ast), creatine phosphokinase (cpk), lactate dehydrogenase (ldh), prothrombin time (pt), activated partial thromboplastin time (aptt), and thrombocyte and fibrinogen levels, were consistent with many clinical studies i...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
cell journal

جلد ۸، شماره ۳، صفحات ۱۹۶-۲۰۳

کلمات کلیدی

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023